Accelerate.EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211. A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects. Accelerate.EU's core objectives are: Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients. • Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU. • Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durability Accelerate.EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers. The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics. Accelerate.EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients. Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.

Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry partners, European and medical societies focusing on training and education, a patient advocacy group spearheaded by an experienced project management group. Thera4Care aims to establish a European network of radiotheranostics centres able to rapidly develop and implement radiotheranostics tools and solutions to drive precision health. The overarching vision of Thera4Care is to revolutionise radiotheranostics procedures by establishing, implementing, and disseminating standardised scalable methods to produce and efficiently administer key radiotheranostics solutions. Thera4Care focus is on developing diagnostic and therapeutic ligands tailored to key disease areas (such as solid tumours), aligning with the growing significance of multi-modal radiotheranostics solutions dominated by radionuclide-based therapy and companion diagnostics. Thera4Care project is scheduled for 5 years and consists of 9 work packages. WP1 handles Project Management, WP2 focuses on Regulatory aspects, WP3 plans Preclinical studies, WP4 provides Supply chain, WP5 develops Clinical Trials, WP6 generates AI models, WP7 focuses on Dosimetry, WP8 develops Precision Imaging components, while WP9 focuses on Education and Dissemination. Thera4Care will advocate for the progress of radiotheranostics, with the goal of increasing medical knowledge and enhancing treatment efficacy for improved patient outcomes. Concurrently, aims to coordinate scientific initiatives across European landscapes, leveraging a comprehensive and multimodal approach to cancer therapy applicable to various cancer types. Lastly, will work on the establishment of sustainable supply and production networks and the upscaling of production methodologies and supply chains across the public and private sectors, to enhance the availability of radionuclides.